New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. (&#34;Cellebrite&#34; or the &#34;Company&#34;)

<p>New York, New York--(Newsfile Corp. - August 17, 2026) - <a href="https://api.newsfilecorp.com/redirect/EZqnQUvK3W">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CLBT">CLBT</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/xEp2DfV2AQ">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Cellebrite investor and have suffered losses, or if you have information that could assist in the Cellebrite investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/7nkPqSPBgw"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On August 13, 2026, Cellebrite reported second-quarter results, including total Annual Recurring Revenue ("ARR") of $507.8 million, missing the lower end of the Company's previous projection for ARR in the range of $510 million to $513 million.  The Company also cut its full-year annual recurring revenue guidance by roughly $15 million at the midpoint and cited "a foreign entity permit requirement, which is applied to cloud technology" that delayed certain deals.  Cellebrite simultaneously announced an abrupt CEO change, replacing CEO Tom Hogan with Shiv Ramji, effective immediately. </p><p>Following this news, the price of Cellebrite stock fell $4.45 per share, or 29%, to close at $10.80 per share August 13, 2026.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/ejrAkIQwbL">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/87BbnCm2pe">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/ppB10U3xJR">https://www.kaplanfox.com/case/cellebrite-di-ltd-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/309966_d1552672f4c20b0a_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/YEPAXfxvm1">https://www.newsfilecorp.com/release/309966</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/309966/197" alt="" /></p>

CLBT

Kaplan Fox & Kilsheimer LLP Announces an Investigation into Cellebrite DI Ltd. (CLBT) for Possible Securities Law Violations

Kaplan Fox investigation into Cellebrite raises concerns after ARR miss and CEO change

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. (&amp;#34;Cellebrite&amp;#34; or the &amp;#34;Company&amp;#34;)</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kaplan Fox &amp; Kilsheimer LLP is probing Cellebrite for potential securities violations after the Q2 ARR miss and an abrupt CEO change. The development follows a 29% stock drop, signaling investor concern and elevated governance risk. Outcomes could affect CLBT&#039;s growth trajectory and valuation depending on any resulting litigation or settlements.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Q2 ARR $507.8M, below guidance of $510–$513M. Guidance cut ~$15M mid.</li><li>CEO change: Tom Hogan out, Shiv Ramji in, effective immediately.</li><li>Cellebrite stock fell 29% to $10.80 on Aug 13, 2026.</li><li>Kaplan Fox leads securities investigation against Cellebrite.</li><li>Monitor potential litigation outcomes and their impact on cash flow.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cellebrite DI Ltd (CLBT)</strong>: Subject of the investigation; potential securities violations; stock action notable.</li><li><strong>Bank of America Corporation (BAC)</strong>: Referenced as context for large stock settlements; not a CLBT-specific claim.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Lead law firm conducting the securities inquiry; impact on CLBT uncertain.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category Type: Legal. Fits due to securities investigation and potential litigation implications affecting governance and valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Q2 ARR miss ($507.8M) vs guidance ($510–$513M) signals revenue risk.</li><li>CEO transition adds governance/execution risk.</li><li>Stock closed at $10.80 after a 29% drop on Aug 13, 2026.</li><li>Solicitation by Kaplan Fox could extend investor focus but not proven material.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q2 ARR: $507.8M.</li><li>Full-year ARR guidance cut by midpoint ~ $15M.</li><li>Prior ARR guidance range: $510–$513M.</li><li>CEO replacement: Tom Hogan replaced by Shiv Ramji, effective immediately.</li><li>Aug 13, 2026: stock closed at $10.80, down 29%.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term CLBT downside risk from the investigation; clarity within 1–3 quarters will shape risk/reward.</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - August 17, 2026) - <a href="https://api.newsfilecorp.com/redirect/EZqnQUvK3W">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CLBT">CLBT</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/xEp2DfV2AQ">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Cellebrite investor and have suffered losses, or if you have information that could assist in the Cellebrite investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/7nkPqSPBgw"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On August 13, 2026, Cellebrite reported second-quarter results, including total Annual Recurring Revenue ("ARR") of $507.8 million, missing the lower end of the Company's previous projection for ARR in the range of $510 million to $513 million.  The Company also cut its full-year annual recurring revenue guidance by roughly $15 million at the midpoint and cited "a foreign entity permit requirement, which is applied to cloud technology" that delayed certain deals.  Cellebrite simultaneously announced an abrupt CEO change, replacing CEO Tom Hogan with Shiv Ramji, effective immediately. </p><p>Following this news, the price of Cellebrite stock fell $4.45 per share, or 29%, to close at $10.80 per share August 13, 2026.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/ejrAkIQwbL">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/87BbnCm2pe">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/ppB10U3xJR">https://www.kaplanfox.com/case/cellebrite-di-ltd-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/309966_d1552672f4c20b0a_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/YEPAXfxvm1">https://www.newsfilecorp.com/release/309966</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/309966/197" alt="" /></p>

Kaplan Fox & Kilsheimer LLP is probing Cellebrite for potential securities violations after the Q2 ARR miss and an abrupt CEO change. The development follows a 29% stock drop, signaling investor concern and elevated governance risk. Outcomes could affect CLBT's growth trajectory and valuation depending on any resulting litigation or settlements.

News insight

Kaplan Fox & Kilsheimer LLP Announces an Investigation into Cellebrite DI Ltd. (CLBT) for Possible Securities Law Violations

AI summary

Sentiment rationale

Key facts

Legal